Psyence Group Inc. Announces Resignation of Board Member Marvin Singer

LOS ANGELES- Psyence Group Inc a clinical-stage life science biotechnology firm at the forefront of utilizing nature-derived psilocybin for mental health and wellbeing, today announced the resignation of Mr. Marvin Singer from his role as a Non-Executive Director. Citing personal reasons for his departure, Mr. Singer’s resignation marks the end of a significant era for the company, having been a vital member of the board since Psyence Group’s listing in January 2021.

During his tenure, Mr. Singer contributed extensively to the strategic development and growth of Psyence Group. His experience and insights have been a cornerstone in guiding the company through crucial phases of its evolution. Mr. Jody Aufrichtig, Executive Chairman of Psyence Group, expressed gratitude for Mr. Singer’s commitment and the substantial impact he has made. “Marvin’s strategic thinking and wealth of experience have been invaluable to our board and have played a crucial role in our company’s growth,” he stated.

In response to this development, the board of directors has promptly commenced the process of identifying a suitable replacement for Mr. Singer. This move underscores the company’s dedication to sustaining a robust and diverse board, reflective of the values and objectives that Psyence Group Inc. upholds.

The company remains focused on its mission to pioneer in the field of psychopharmacology, leveraging the therapeutic potential of psilocybin in mental health treatment. The departure of Mr. Singer, though significant, does not deter Psyence Group from its path of innovation and its commitment to enhancing mental health and wellbeing through groundbreaking research and development.